Autolus Therapeutics (AUTL) Operating Leases (2019 - 2025)

Autolus Therapeutics (AUTL) has reported Operating Leases for 7 consecutive years, with $71.4 million the latest figure, recorded in Q4 2025.

• Quarterly Operating Leases rose 35.64% year-over-year to $71.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $71.4 million (up 35.64% YoY) and the FY2025 annual result came in at $71.4 million, up 35.64% from the prior year.
• Operating Leases rose to $71.4 million in Q4 2025 per AUTL's latest filing, from $65.8 million in the prior quarter.
• Over the last five years, Operating Leases for AUTL reached as high as $71.4 million in Q4 2025 and fell as low as $11.3 million in Q3 2022.
• A 5-year average of $38.7 million and a median of $45.8 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases slumped 64.93% — and 2023, when it surged 315.27%.
• Year by year, Operating Leases stood at $21.0 million in 2021, then increased by 15.52% to $24.3 million in 2022, then soared by 118.37% to $53.0 million in 2023, then slipped by 0.64% to $52.6 million in 2024, then soared by 35.64% to $71.4 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $71.4 million, $65.8 million, and $64.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.